Ghasemi et al.’s study highlighted COX-2 as a crucial diagnostic marker distinguishing malignant melanoma from benign neoplasms, identifying a significant association between COX-2 levels and tumor stage positioning COX-2 as an effective diagnostic tool for identifying malignant melanoma. The gene discussed is PTGS2; the disease is benign neoplasm.